Braveheart Bio (NASDAQ:BRVE) CFO Buys $499,986.00 in Stock

Braveheart Bio, Inc. (NASDAQ:BRVE) CFO James Paul Rickey purchased 27,777 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The stock was purchased at an average price of $18.00 per share, with a total value of $499,986.00. Following the completion of the purchase, the chief financial officer directly owned 520,927 shares of the company’s stock, valued at approximately $9,376,686. This represents a 5.63% increase in their position. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.

Braveheart Bio Trading Up 0.7%

BRVE traded up $0.20 on Friday, hitting $30.00. 565,846 shares of the company’s stock were exchanged. Braveheart Bio, Inc. has a twelve month low of $28.47 and a twelve month high of $32.00.

Braveheart Bio Company Profile

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.